B
Bull
Bull · 25%SYBX
$1.87
情景价格
$0.560
-0.280 (-50.00%)收盘时
Loading chart…
- High
- 0.777
- Open
- 0.777
- VWAP
- 0.63
- Vol
- 3.57M
- Mkt Cap
- 18.15M
- Low
- 0.560
- Amount
- 2.26M
- EV/EBITDA, TTM
- 0.00
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Analyst Ratings (1)
Buy
1 Buy
0 Hold
0 Sell
Current: 0.56
最低
—
平均
—
最高
—
HC Wainwright & Co.
Hold
—
2024-03-20
HC Wainwright & Co.
2024-03-20
目标价
—
Hold
HC Wainwright & Co.
Strong Sell
—
2024-02-09
HC Wainwright & Co.
2024-02-09
目标价
—
Strong Sell
Leerink Partners
Hold
$1
2024-02-09
Leerink Partners
2024-02-09
目标价
$1
Hold
Chardan Capital
Hold
—
2024-02-09
Chardan Capital
2024-02-09
目标价
—
Hold
Alliance Global Partners
Strong Buy
$30
2023-12-11
Alliance Global Partners
2023-12-11
目标价
$30
Strong Buy
估值指标
The current forward P/E ratio for Synlogic Inc (SYBX) is -2.49, compared to its 5-year average forward P/E of -1.88.
Alphio AI Price Scenarios for SYBX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SYBX
事件时间线
资讯
SYBX FAQ — answered by Alphio AI
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
1 analysts cover SYBX: 1 rate it Buy, 0 Hold and 0 Sell.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。